Q1 2025 Earnings Estimate for ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Issued By HC Wainwright

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of ORIC Pharmaceuticals in a report released on Wednesday, May 8th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($0.47) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $21.00 price target on the stock. The consensus estimate for ORIC Pharmaceuticals' current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for ORIC Pharmaceuticals' Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.97) EPS.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its quarterly earnings data on Monday, March 11th. The company reported ($0.49) earnings per share for the quarter, hitting the consensus estimate of ($0.49).

Other equities analysts have also recently issued research reports about the company. JPMorgan Chase & Co. cut their price target on ORIC Pharmaceuticals from $19.00 to $18.00 and set an "overweight" rating for the company in a report on Wednesday, March 27th. Cantor Fitzgerald initiated coverage on ORIC Pharmaceuticals in a report on Friday, February 23rd. They issued an "overweight" rating for the company. Citigroup cut their price target on ORIC Pharmaceuticals from $15.00 to $14.00 and set a "buy" rating for the company in a report on Tuesday. Finally, Wedbush upped their price target on ORIC Pharmaceuticals from $12.00 to $20.00 and gave the company an "outperform" rating in a report on Friday, March 1st. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $20.00.

ORIC Pharmaceuticals Price Performance

Shares of NASDAQ ORIC traded down $0.51 during trading hours on Friday, hitting $8.99. 242,533 shares of the company's stock were exchanged, compared to its average volume of 535,079. ORIC Pharmaceuticals has a 1-year low of $4.91 and a 1-year high of $16.65. The stock has a market capitalization of $606.11 million, a price-to-earnings ratio of -4.54 and a beta of 1.19. The company's 50-day moving average price is $11.78 and its 200-day moving average price is $9.96.

Institutional Investors Weigh In On ORIC Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Vivo Capital LLC bought a new position in ORIC Pharmaceuticals in the 3rd quarter valued at $4,707,000. Vanguard Group Inc. lifted its stake in shares of ORIC Pharmaceuticals by 27.9% in the 1st quarter. Vanguard Group Inc. now owns 2,882,055 shares of the company's stock valued at $39,628,000 after purchasing an additional 629,536 shares during the period. Alkeon Capital Management LLC lifted its stake in shares of ORIC Pharmaceuticals by 16.8% in the 3rd quarter. Alkeon Capital Management LLC now owns 3,479,289 shares of the company's stock valued at $21,050,000 after purchasing an additional 500,000 shares during the period. Euclidean Capital LLC lifted its stake in shares of ORIC Pharmaceuticals by 32.4% in the 3rd quarter. Euclidean Capital LLC now owns 989,410 shares of the company's stock valued at $5,986,000 after purchasing an additional 241,860 shares during the period. Finally, Jump Financial LLC lifted its stake in shares of ORIC Pharmaceuticals by 104.8% in the 3rd quarter. Jump Financial LLC now owns 32,149 shares of the company's stock valued at $195,000 after purchasing an additional 16,449 shares during the period. 95.05% of the stock is currently owned by institutional investors.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.